ESMO 2022: PRESTO - A Phase 3 Androgen Annihilation in Biochemically Relapsed Prostate Cancer
Rahul Aggarwal describes the results of the randomized phase 3 PRESTO study that examined the effects of androgen suppressants on biochemically relapsed prostate cancer.
670 Madison Ave.
Manalapan, NJ 07726
Contributors and Partners
Cancer Nursing Today
Urban Health Today
Blood Cancers Today
© 2022 Mashup Media, LLC. All rights reserved.